Tempest Therapeutics Says Amezalpat Receives US FDA Fast Track Status As Treatment for Liver Cancer

MT Newswires Live

Feb 10, 2025

Tempest Therapeutics (TPST) said Monday the US Food and Drug Administration granted fast track designation to amezalpat for the potential treatment of hepatocellular carcinoma, a type of liver cancer.

The company said the designation allows for increased communication with the FDA and potential eligibility for accelerated approval and priority review. The designation follows an orphan drug designation in January, Tempest added.

Tempest said amezalpat is being evaluated in combination with atezolizumab and bevacizumab in a global phase 1b/2 trial for first-line treatment of unresectable or metastatic hepatocellular carcinoma.

Shares of the company were up 1.8% in recent Monday trading.

Price: 0.89, Change: +0.02, Percent Change: +1.77

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2510286921"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2510286921\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2510286921?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-10 23:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2510286921","market":"fut","top_or_hot":-1,"title":"Tempest Therapeutics Says Amezalpat Receives US FDA Fast Track Status As Treatment for Liver Cancer","media":"MT Newswires Live","content":"<html><body><p> Tempest <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TPST) said Monday the US Food and Drug Administration granted fast track designation to amezalpat for the potential treatment of hepatocellular carcinoma, a type of liver cancer.</p><p>The company said the designation allows for increased communication with the FDA and potential eligibility for accelerated approval and priority review. The designation follows an orphan drug designation in January, Tempest added.</p><p>Tempest said amezalpat is being evaluated in combination with atezolizumab and bevacizumab in a global phase 1b/2 trial for first-line treatment of unresectable or metastatic hepatocellular carcinoma.</p><p>Shares of the company were up 1.8% in recent Monday trading.</p><p>Price: 0.89, Change: +0.02, Percent Change: +1.77</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempest Therapeutics Says Amezalpat Receives US FDA Fast Track Status As Treatment for Liver Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempest Therapeutics Says Amezalpat Receives US FDA Fast Track Status As Treatment for Liver Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-10 23:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Tempest <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TPST) said Monday the US Food and Drug Administration granted fast track designation to amezalpat for the potential treatment of hepatocellular carcinoma, a type of liver cancer.</p><p>The company said the designation allows for increased communication with the FDA and potential eligibility for accelerated approval and priority review. The designation follows an orphan drug designation in January, Tempest added.</p><p>Tempest said amezalpat is being evaluated in combination with atezolizumab and bevacizumab in a global phase 1b/2 trial for first-line treatment of unresectable or metastatic hepatocellular carcinoma.</p><p>Shares of the company were up 1.8% in recent Monday trading.</p><p>Price: 0.89, Change: +0.02, Percent Change: +1.77</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2510286921","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2510286921","pubTimestamp":1739201421,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tempest Therapeutics  said Monday the US Food and Drug Administration granted fast track designation to amezalpat for the potential treatment of hepatocellular carcinoma, a type of liver cancer.The company said the designation allows for increased communication with the FDA and potential eligibility for accelerated approval and priority review. The designation follows an orphan drug designation in January, Tempest added.Tempest said amezalpat is being evaluated in combination with atezolizumab and bevacizumab in a global phase 1b/2 trial for first-line treatment of unresectable or metastatic hepatocellular carcinoma.Shares of the company were up 1.8% in recent Monday trading.Price: 0.89, Change: +0.02, Percent Change: +1.77","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","TPST":"Tempest Therapeutics Inc.","BK4104":"贸易公司与经销商","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","FAST":"快扣","BK4139":"生物科技"},"translate_title":"Tempest Therapeutics表示Amezalpat获得美国FDA肝癌治疗快速通道地位","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"TPST":0.9,"FAST":1},"content_text":"Tempest Therapeutics (TPST) said Monday the US Food and Drug Administration granted fast track designation to amezalpat for the potential treatment of hepatocellular carcinoma, a type of liver cancer.The company said the designation allows for increased communication with the FDA and potential eligibility for accelerated approval and priority review. The designation follows an orphan drug designation in January, Tempest added.Tempest said amezalpat is being evaluated in combination with atezolizumab and bevacizumab in a global phase 1b/2 trial for first-line treatment of unresectable or metastatic hepatocellular carcinoma.Shares of the company were up 1.8% in recent Monday trading.Price: 0.89, Change: +0.02, Percent Change: +1.77","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}